Sei Investments Co. Purchases 79,088 Shares of LivaNova PLC $LIVN

Sei Investments Co. raised its position in LivaNova PLC (NASDAQ:LIVN) by 56.6% during the first quarter, Holdings Channel.com reports. The institutional investor owned 218,805 shares of the company’s stock after purchasing an additional 79,088 shares during the quarter. Sei Investments Co.’s holdings in LivaNova were worth $13,907,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. raised its stake in shares of LivaNova by 159.9% in the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after acquiring an additional 267 shares during the last quarter. State of Wyoming bought a new stake in LivaNova during the 2nd quarter worth approximately $31,000. Quarry LP bought a new stake in LivaNova during the 3rd quarter worth approximately $36,000. EverSource Wealth Advisors LLC increased its holdings in LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after purchasing an additional 639 shares in the last quarter. Finally, Covestor Ltd raised its position in LivaNova by 108.6% in the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after purchasing an additional 392 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

LivaNova Stock Performance

LIVN stock opened at $81.05 on Friday. The company has a 50 day moving average price of $78.96 and a 200 day moving average price of $70.06. LivaNova PLC has a fifty-two week low of $41.01 and a fifty-two week high of $85.27. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. The stock has a market capitalization of $4.45 billion, a PE ratio of 41.56 and a beta of 0.86.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. The firm had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period last year, the company earned $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Analysts forecast that LivaNova PLC will post 3.73 EPS for the current year.

Insider Transactions at LivaNova

In related news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the transaction, the director owned 7,228 shares in the company, valued at $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.35% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Barclays boosted their price objective on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Robert W. Baird lowered their target price on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Zacks Research raised LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Finally, KeyCorp increased their price objective on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, June 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, LivaNova currently has a consensus rating of “Moderate Buy” and an average price target of $81.38.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.